Questions and answers on the outcome of assessment on use of Revolade in treatment of severe aplastic anaemia in children

New product information wording: extracts from PRAC recommendations on signals adopted at the 7-10 July 2025 PRAC

Human medicines European public assessment report (EPAR): Piqray, alpelisib, Date of authorisation: 27/07/2020, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Fanskya, Mozafancogene autotemcel, Status: Application withdrawn

Human medicines European public assessment report (EPAR): Oczyesa, octreotide, Date of authorisation: 30/06/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Vimkunya, Chikungunya vaccine (recombinant, adsorbed), Date of authorisation: 28/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Ninlaro, ixazomib, Date of authorisation: 21/11/2016, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Keppra, levetiracetam, Date of authorisation: 29/09/2000, Revision: 56, Status: Authorised

Human medicines European public assessment report (EPAR): Myalepta, metreleptin, Date of authorisation: 29/07/2018, Revision: 14, Status: Authorised

First webinar on new approach methodologies (NAMs) in ecotoxicology: State of the science for bioaccumulation, Online, from 10 September 2025, 14:00 (CEST) to 10 September 2025, 15:00 (CEST)